Ceapro Inc V.CZO

Ceapro is cheap

[laurencelefou]

The market Cap is $57,202,000 ($0.71 X 80,566,176 shares) 2022-11-18
Cash on hand is $12,910,000.
Cash from options in the money is $1,129,000.
No debt.
Enterprise value (EV) is $43,162,000.

Trailing twelve months (TTM) operating cash flows are $6,317,000.
Cash Flow yield is 13.9% ($6,317,000 / $43,162,000).
Or
EV multiple is 6.3 ($43,162,000 / $6,317,000).

TTM revenue is $19,079,000
TTM operating cash flows are $6,317,000
The operating cash flow margin is 33.1%.

Some fiscal years have been better than others, but since 2014, revenue has grown at an annual rate of ±10%. Excel worksheet (TTM / 2014)^(1/8)-1.

Ceapro has enough cash to build a plant with a 50 or 100 litres vessel.

Ceapro is cheap and will trade at a higher valuation.
 
https://apps.tmx.com/TSXVenture/TSXVentureHttpController?GetPage=MarketCapDailyTradingSummary&SECURITY_ID=34781&MARKET_ID=CDNX&SEC_SYM_SID=2&HC_FLAG1=&HC_FLAG2=&isShowRange=on&StartMonth=8&StartDay=21&StartYear=2022&EndMonth=11&EndDay=19&EndYear=2022&x=11&y=9

[Ciao]

Welcome to the board. How did you hear about the company?

[laurencelefou]

Smallcap discoveries.

[Ciao]

As for how you came upon this small cap via "discoveries", it's a large part as to why the share price and market cap is at its' current valuation, it really hasn't been discovered and that's the challenge inherent for micro/nano caps; the story needs to be told 

[Hopeforthebest]

Just curious if Czo is such a slam dunk why do all major investor adviser steer clear of Czo? Why out of millions of individual trades on a daily basis, Czo has consistently seen maybe 5-10:trade max on a daily basis not for a few days or weeks or months but years why? 3qrtr results show reduced sales, increased expense reduced r&d expenditures, a triple whammy, with all those so called

[laurencelefou]

In the short term, there are no stock investments that is a sure ‘’slam dunk’’ or Goooaaalll.   I do not care about the short-term, I look for long-term growth stories, with limited downside risk, that are profitable and that have more cash than debt.   Ceapro has little control over its revenue, Symrise generates 90% of Ceapro’s revenue.   For Q3-2022, Ceapro posted revenue of

[Hopeforthebest]

You seem to quote some very impressive people but I would hazard to guess that Czo is not part of their stock profolio. As for patience yes 5 years ago Czo was trading above $2 per share, patience. as for,all those shares am available , the 156 sold on Thursday really made a dent in those 76 million available or the shares being bought through insider trading, a big fat ZERO. I am kind of

[laurencelefou]

I had a look at the 2015 and 2016 balance sheet and for those two years Ceapro was very profitable.  Revenues were $13,674,000 (2016) and $10,677,000 (2015) and operating cash flows (OCF) were $4,885,000 (2016) and $3,982,000 (2015).  These numbers would have caught my attention, but the company did not come under my radar.   From October 2015 to July 2016, the share price climbed

[Hopeforthebest]

wow another gagnon mouthpiece. Maybe if gagnon paid as much attention to propmoting as he does trying to recruit the stockhouse board we would get more than 1 or 2 trades a day. Maybe gagnon should buy some shares himself or get his friends like the famous ronnie dip into his pockets and buy some share. You know lauren, this stock has done basically F all in the last five years except nose dive

[prophetoffactz]

Hopeforthebest, "You know lauren, this stock has done basically F all in the last five years except nose dive." The truth: CZO is up 34% in the last 5 years vs. the S&P Biotech ETF which is down 2.55% over the last 5 years.  Year-to-date CZO is up 22.95% vs. the S&P Biotech ETF which is down 30.81%.

[prophetoffactz]

CZO is cheap based on its current revenue generating, growing, and profitable base business alone. It has the only commercial-scale natural avenanthramide production capacity in the world. The base business grows at about 10% per year. CZO's distribution partner, US$15.6 billion Symrise, signed a 3 year deal plus 3 year option this year that may result in 'accelerated' sales according